Amyotrophic lateral sclerosis: exploring pathophysiology in the context of treatment

References

• Goutman SA. Diagnosis and clinical management of amyotrophic lateral sclerosis and other motor neuron disorders. Continuum. 2017;23:1332–59.
   PubMedGoogle Scholar
• Rubio MA, Herrando-Grabulosa M, Navarro X. Sensory involvement in amyotrophic lateral sclerosis. Int J Mol Sci 2022;23:15521.
   PubMed Web of Science ®Google Scholar
• Ryan M, Heverin M, McLaughlin RL, Hardiman O. Lifetime risk and heritability of amyotrophic lateral sclerosis. JAMA Neurol. 2019;76:1367–74.
   PubMed Web of Science ®Google Scholar
• Juneja T, Pericak-Vance MA, Laing NG, Dave S, Siddique T. Prognosis in familial amyotrophic lateral sclerosis: progression and survival in patients with glu100gly and ala4val mutations in Cu,Zn superoxide dismutase. Neurology 1997;48:55–7.
   PubMed Web of Science ®Google Scholar
• Huisman MH, de Jong SW, van Doormaal PT, Weinreich SS, Schelhaas HJ, van der Kooi AJ, et al. Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology. J Neurol Neurosurg Psychiatry. 2011;82:1165–70.
   PubMed Web of Science ®Google Scholar
• Wong C, Stavrou M, Elliott E, Gregory JM, Leigh N, Pinto AA, et al. Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. Brain Commun 2021;3:fcab242.
   PubMedGoogle Scholar
• Van Damme P, Dewil M, Robberecht W, Van Den Bosch L. Excitotoxicity and amyotrophic lateral sclerosis. Neurodegener Dis 2005;2:147–59.
   PubMed Web of Science ®Google Scholar
• Lewerenz J, Hewett SJ, Huang Y, Lambros M, Gout PW, Kalivas PW, et al. The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal. 2013;18:522–55.
   PubMed Web of Science ®Google Scholar
• Hall CE, Yao Z, Choi M, Tyzack GE, Serio A, Luisier R, et al. Progressive motor neuron pathology and the role of astrocytes in a human stem cell model of VCP-related ALS. Cell Rep. 2017;19:1739–49.
   PubMed Web of Science ®Google Scholar
• Andrews JA, Jackson CE, Heiman-Patterson TD, Bettica P, Brooks BR, Pioro EP. Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:509–18.
   PubMed Web of Science ®Google Scholar
• Wang SJ, Wang KY, Wang WC. Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience 2004;125:191–201.
   PubMed Web of Science ®Google Scholar
• Carbone M, Duty S, Rattray M. Riluzole elevates GLT-1 activity and levels in striatal astrocytes. Neurochem Int. 2012;60:31–8.
   PubMed Web of Science ®Google Scholar
• Lamanauskas N, Nistri A. Riluzole blocks persistent Na + and Ca2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro. Eur J Neurosci. 2008;27:2501–14.
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005;433:73–7.
   PubMed Web of Science ®Google Scholar
• Melzer N, Meuth SG, Torres-Salazar D, Bittner S, Zozulya AL, Weidenfeller C, et al. A beta-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis. PLOS One. 2008;3:e3149.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Titus S, Kearney M, Yu H, Sherman A, Schoenfeld D, et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13:1083–91.
   PubMed Web of Science ®Google Scholar
• Singh A, Kukreti R, Saso L, Kukreti S. Oxidative stress: a key modulator in neurodegenerative diseases. Molecules. 2019;24:1583.
   PubMed Web of Science ®Google Scholar
• Chiurchiu V, Orlacchio A, Maccarrone M. Is modulation of oxidative stress an answer? The state of the art of redox therapeutic actions in neurodegenerative diseases. Oxid Med Cell Longev. 2016;2016:7909380.
   PubMed Web of Science ®Google Scholar
• Mendez EF, Sattler R. Biomarker development for C9orf72 repeat expansion in ALS. Brain Res. 2015;1607:26–35.
   PubMed Web of Science ®Google Scholar
• Mead RJ, Shan N, Reiser HJ, Marshall F, Shaw PJ. Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nat Rev Drug Discov. 2023;22:185–212.
   PubMed Web of Science ®Google Scholar
• Abe KA, Tsuji S, Itoyama Y, Sobue G, Togo M, Hamada C, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–12.
   PubMed Web of Science ®Google Scholar
• Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? Front Aging Neurosci. 2017;9:68.
   PubMed Web of Science ®Google Scholar
• Liu J, Jiang Y, Zhang G, Lin Z, Du S. Protective effect of edaravone on blood-brain barrier by affecting NRF-2/HO-1 signaling pathway. Exp Ther Med. 2019;18:2437–42.
   PubMed Web of Science ®Google Scholar
• Takayasu Y, Nakaki J, Kawasaki T, Koda K, Ago Y, Baba A, et al. Edaravone, a radical scavenger, inhibits mitochondrial permeability transition pore in rat brain. J Pharmacol Sci. 2007;103:434–7.
   PubMed Web of Science ®Google Scholar
• Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med. 1999;5:347–50.
   PubMed Web of Science ®Google Scholar
• Beal MF. Coenzyme Q10 as a possible treatment for neurodegenerative diseases. Free Radic Res 2002;36:455–60.
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Thompson JL, Levy G, Buchsbaum R, Shefner J, Krivickas LS, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009;66:235–44.
   PubMed Web of Science ®Google Scholar
• Ludolph AC, Bendotti C, Blaugrund E, Chio A, Greensmith L, Loeffler JP, et al. Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph Lateral Scler. 2010;11:38–45.
   PubMed Web of Science ®Google Scholar
• Genç B, Özdinler PH. Moving forward in clinical trials for ALS: motor neurons lead the way please. Drug Discov Today. 2014;19:441–9.
   PubMed Web of Science ®Google Scholar
• Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417:74–8.
   PubMed Web of Science ®Google Scholar
• Kriz J, Nguyen MD, Julien JP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 2002;10:268–78.
   PubMed Web of Science ®Google Scholar
• Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007;6:1045–53.
   PubMed Web of Science ®Google Scholar
• Keller AF, Gravel M, Kriz J. Treatment with minocycline after disease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice. Exp Neurol. 2011;228:69–79.
   PubMed Web of Science ®Google Scholar
• Hetz C, Zhang K, Kaufman RJ. Mechanisms, regulation and functions of the unfolded protein response. Nat Rev Mol Cell Biol. 2020;21:421–38.
   PubMed Web of Science ®Google Scholar
• Schirrmacher V. Mitochondria at work: new insights into regulation and dysregulation of cellular energy supply and metabolism. Biomedicines 2020;8:526.
   PubMed Web of Science ®Google Scholar
• Jeon YM, Kwon Y, Lee S, Kim HJ. Potential roles of the endoplasmic reticulum stress pathway in amyotrophic lateral sclerosis. Front Aging Neurosci. 2023;15:1047897.
   PubMed Web of Science ®Google Scholar
• Bernard-Marissal N, Chrast R, Schneider BL. Endoplasmic reticulum and mitochondria in diseases of motor and sensory neurons: a broken relationship? Cell Death Dis. 2018;9:333.
   PubMed Web of Science ®Google Scholar
• Jankovic M, Novakovic I, Gamil Anwar Dawod P, Gamil Anwar Dawod A, Drinic A, Abdel Motaleb FI, et al. Current concepts on genetic aspects of mitochondrial dysfunction in amyotrophic lateral sclerosis. Int J Mol Sci 2021;22:9832.
   PubMedGoogle Scholar
• Montibeller L, Tan LY, Kim JK, Paul P, de Belleroche J. Tissue-selective regulation of protein homeostasis and unfolded protein response signalling in sporadic ALS. J Cell Mol Med. 2020;24:6055–69.
   PubMed Web of Science ®Google Scholar
• Ramesh N, Pandey UB. Autophagy dysregulation in ALS: when protein aggregates get out of hand. Front Mol Neurosci. 2017;10:263.
   PubMed Web of Science ®Google Scholar
• Lebeau PF, Platko K, Byun JH, Austin RC. Calcium as a reliable marker for the quantitative assessment of endoplasmic reticulum stress in live cells. J Biol Chem. 2021;296:100779.
   PubMed Web of Science ®Google Scholar
• Ryu H, Smith K, Camelo SI, Carreras I, Lee J, Iglesias AH, et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem. 2005;93:1087–98.
   PubMed Web of Science ®Google Scholar
• Roy A, Ghosh A, Jana A, Liu X, Brahmachari S, Gendelman HE, et al. Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson’s disease. PLOS One. 2012;7:e38113.
   PubMed Web of Science ®Google Scholar
• Castro RE, Sola S, Ramalho RM, Steer CJ, Rodrigues CM. The bile acid tauroursodeoxycholic acid modulates phosphorylation and translocation of bad via phosphatidylinositol 3-kinase in glutamate-induced apoptosis of rat cortical neurons. J Pharmacol Exp Ther. 2004;311:845–52.
   PubMed Web of Science ®Google Scholar
• Rodrigues CM, Sola S, Sharpe JC, Moura JJ, Steer CJ. Tauroursodeoxycholic acid prevents Bax-induced membrane perturbation and cytochrome C release in isolated mitochondria. Biochemistry 2003;42:3070–80.
   PubMed Web of Science ®Google Scholar
• Fels JA, Dash J, Leslie K, Manfredi G, Kawamata H. Effects of PB-TURSO on the transcriptional and metabolic landscape of sporadic ALS fibroblasts. Ann Clin Transl Neurol. 2022;9:1551–64.
   PubMed Web of Science ®Google Scholar
• Gribkoff VK, Bozik ME. KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis. CNS Neurosci Ther. 2008;14:215–26.
   PubMed Web of Science ®Google Scholar
• Bordet T, Buisson B, Michaud M, Drouot C, Galea P, Delaage P, et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther. 2007;322:709–20.
   PubMed Web of Science ®Google Scholar
• Cudkowicz M, Bozik ME, Ingersoll EW, Miller R, Mitsumoto H, Shefner J, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med. 2011;17:1652–6.
   PubMed Web of Science ®Google Scholar
• Lenglet T, Lacomblez L, Abitbol JL, Ludolph A, Mora JS, Robberecht W, et al. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur J Neurol. 2014;21:529–36.
   PubMed Web of Science ®Google Scholar
• Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci. 2019;13:1310.
   PubMed Web of Science ®Google Scholar
• McCampbell A, Cole T, Wegener AJ, Tomassy GS, Setnicka A, Farley BJ, et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clin Invest. 2018;128:3558–67.
   PubMed Web of Science ®Google Scholar
• Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, et al. Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383:109–19.
   PubMed Web of Science ®Google Scholar
• Biogen and ionis announce topline phase 1 study results of investigational drug in C9orf72 amyotrophic lateral sclerosis [press release]. March 28, 2022. 2022.
   Google Scholar
• Liu Y, Andreucci A, Iwamoto N, Yin Y, Yang H, Liu F, et al. Preclinical evaluation of WVE-004, aninvestigational stereopure oligonucleotide for the treatment of C9orf72-associated ALS or FTD. Mol Ther Nucleic Acids. 2022;28:558–70.
   PubMedGoogle Scholar
• Wave life sciences announces positive update to ongoing phase 1b/2a FOCUS-C9 study driven by potent, durable reductions of poly(GP) with low, single doses of WVE-004 [press release]. April 4, 2022. 2022.
   Google Scholar
• Wave life sciences announces topline results from phase 1b/2a FOCUS-C9 study of WVE-004 for C9orf72-associated amyotrophic lateral sclerosis and frontotemporal dementia [press release]. May 23 2023. 2023.
   Google Scholar
• Liu J, Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front Immunol. 2017;8:1005.
   PubMed Web of Science ®Google Scholar
• Clarke BE, Patani R. The microglial component of amyotrophic lateral sclerosis. Brain. 2020;143:3526–39.
   PubMed Web of Science ®Google Scholar
• Zhao W, Beers DR, Appel SH. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol. 2013;8:888–99.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol. 2006;60:22–31.
   PubMed Web of Science ®Google Scholar
• Lauria G, Dalla Bella E, Antonini G, Borghero G, Capasso M, Caponnetto C, et al. Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study. J Neurol Neurosurg Psychiatry. 2015;86:879–86.
   PubMed Web of Science ®Google Scholar
• Meininger V, Drory VE, Leigh PN, Ludolph A, Robberecht W, Silani V. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial. Amyotroph Lateral Scler. 2009;10:378–83.
   PubMed Web of Science ®Google Scholar
• Miller RG, Zhang R, Bracci PM, Azhir A, Barohn R, Bedlack R, et al. Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: pre-specified and post hoc analyses. Muscle Nerve. 2022;66:39–49.
   PubMed Web of Science ®Google Scholar
• Dupuis L, Dengler R, Heneka MT, Meyer T, Zierz S, Kassubek J, et al. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLOS One. 2012;7:e37885.
   PubMed Web of Science ®Google Scholar
• Ravulizumab phase 3 trial in ALS discontinued due to lack of efficacy [press release]. August 24, 2021.
   Google Scholar
• Piepers S, Veldink JH, de Jong SW, van der Tweel I, van der Pol WL, Uijtendaal EV, et al. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann Neurol. 2009;66:227–34.
   PubMed Web of Science ®Google Scholar
• Westarp ME, Bartmann P, Rössler J, Geiger E, Westphal KP, Schreiber H, et al. Antiretroviral therapy in sporadic adult amyotrophic lateral sclerosis. Neuroreport 1993;4:819–22.
   PubMed Web of Science ®Google Scholar
• Scelsa SN, MacGowan DJL, Mitsumoto H, Imperato T, LeValley AJ, Liu MH, et al. A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS. Neurology 2005;64:1298–300.
   PubMed Web of Science ®Google Scholar
• Ionis opening phase 3 trial of ION363, antisense therapy for FUS-ALS. [press release]. 2021.
   Google Scholar
• Korobeynikov VA, Lyashchenko AK, Blanco-Redondo B, Jafar-Nejad P, Shneider NA. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat Med. 2022;28:104–16.
   PubMed Web of Science ®Google Scholar
• Becker LA, Huang B, Bieri G, Ma R, Knowles DA, Jafar-Nejad P, et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 2017;544:367–71.
   PubMed Web of Science ®Google Scholar
• Gagliardi D, Pagliari E, Meneri M, Melzi V, Rizzo F, Comi GP, et al. Stathmins and motor neuron diseases: pathophysiology and therapeutic targets. Biomedicines 2022;10:711.
   PubMed Web of Science ®Google Scholar
• Klim JR, Williams LA, Limone F, Guerra San Juan I, Davis-Dusenbery BN, Mordes DA, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22:167–79.
   PubMed Web of Science ®Google Scholar
• Baughn MW, Melamed Z, López-Erauskin J, Beccari MS, Ling K, Zuberi A, et al. Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies. Science. 2023;379:1140–9.
   PubMed Web of Science ®Google Scholar
• Fareh M, Yeom KH, Haagsma AC, Chauhan S, Heo I, Joo C. TRBP ensures efficient Dicer processing of precursor microRNA in RNA-crowded environments. Nat Commun. 2016;7:13694.
   PubMed Web of Science ®Google Scholar
• Genge A, Berube-Desrosiers M, Zinman L, Shoesmith C, Salzman M, Schott R, et al. A phase 1, multicenter, open label, single-ascending dose study to evaluate safety, tolerability, and pharmacokinetics of AP-101 in familial and sporadic amyotrophic lateral sclerosis (ALS) (4484). Neurology 2021;96:4484.
   Web of Science ®Google Scholar
• Stutzbach LD, Xie SX, Naj AC, Albin R, Gilman S, Lee VMY, et al. The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer’s disease. Acta Neuropathol Commun. 2013;1:31.
   PubMed Web of Science ®Google Scholar
• Smith HL, Mallucci GR. The unfolded protein response: mechanisms and therapy of neurodegeneration. Brain. 2016;139:2113–21.
   PubMed Web of Science ®Google Scholar
• Gibson LC, Hastings SF, McPhee I, Clayton RA, Darroch CE, Mackenzie A, et al. The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family. Eur J Pharmacol. 2006;538:39–42.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang H, Ying Z, Gao Q. Ibudilast enhances the clearance of SOD1 and TDP-43 aggregates through TFEB-mediated autophagy and lysosomal biogenesis: the new molecular mechanism of Ibudilast and its implication for neuroprotective therapy. Biochem Biophys Res Commun. 2020;526:231–8.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Bravver E, Sanjak M, Langford V, Moore L, Smith N, et al. Adaptive design single center phosphodiesterase type 4 (PDE4) inhibitor–ibudilast (MN-166-ALS-1201) phase 1b/2a clinical trial double-blind (DB) with open label extension (OLE)[NCT02238626] for amyotrophic lateral sclerosis (ALS) patients [1] not requiring non-invasive ventilation (no NIV) up to 5 years (Early Cohort–EC) and [2] requiring non-invasive ventilation (NIV) up to 10 years (advanced NIV cohort–ANC) from disease onset–report of clinical trial DB, OLE and post-treatment cessation epochs–per-protocol (PP) treatment completion associated with improved survival and post treatment cessation loss of muscle strength. Neurology. 2017;88:127.
   Google Scholar
• Cho K. Emerging roles of complement protein C1q in neurodegeneration. Aging Dis. 2019;10:652–63.
   PubMed Web of Science ®Google Scholar
• Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Castéran N, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLOS One. 2009;4:e7258.
   PubMed Web of Science ®Google Scholar
• Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hernandez M, et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:5–14.
   PubMed Web of Science ®Google Scholar
• Alliance briefing note – AB science masitinib [press release]. International Alliance of ALS/MND Associations. August 2022.
   Google Scholar
• Announces positive results from a proof-of-concept academic clinical study for COYA 302 in amyotrophic lateral sclerosis (ALS) [press release]. Coya Therapeutics, Inc. March 21, 2023. 2023.
   Google Scholar
• Roy C. 2022. Breaking down the MIROCALS clinical trial results. https://mndresearch.blog/2022/12/06/breaking-down-the-mirocals-clinical-trial-results/. Accessed September 27th, 2023.
   Google Scholar
• Gold J, Rowe DB, Kiernan MC, Vucic S, Mathers S, van Eijk RPA, et al. Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:595–604.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330:585–91.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383:919–30.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Hendrix S, Dickson SP, Knowlton N, Macklin EA, Berry JD, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021;63:31–9.
   PubMed Web of Science ®Google Scholar
• Miller T, Cudkowicz M, Genge A, Shaw P, Sobue G, Cochrane T, et al. Evaluating efficacy and safety of tofersen in adults with SOD1-ALS: results from the Phase 3 VALOR Trial and open-label extension. Annual Meeting of the European Network to Cure ALS (ENCALS). 2022.
   Google Scholar
• Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022;387:1099–110.
   PubMed Web of Science ®Google Scholar
• Brown HR, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162–72.
   PubMed Web of Science ®Google Scholar
• Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17085.
   PubMed Web of Science ®Google Scholar
• Jaiswal MK. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019;39:733–48.
   PubMed Web of Science ®Google Scholar
• Wobst HJ, Mack KL, Brown DG, Brandon NJ, Shorter J. The clinical trial landscape in amyotrophic lateral sclerosis-past, present, and future. Med Res Rev. 2020;40:1352–84.
   PubMed Web of Science ®Google Scholar
• Cunha-Oliveira T, Montezinho L, Mendes C, Firuzi O, Saso L, Oliveira PJ, et al. Oxidative stress in amyotrophic lateral sclerosis: pathophysiology and opportunities for pharmacological intervention. Oxid Med Cell Longev. 2020;2020:5021694.
   PubMed Web of Science ®Google Scholar
• Fujisawa A, Yamamoto Y. Edaravone, a potent free radical scavenger, reacts with peroxynitrite to produce predominantly 4-NO-edaravone. Redox Rep. 2016;21:98–103.
   PubMed Web of Science ®Google Scholar
• Kamogawa E, Sueishi Y. A multiple free-radical scavenging (MULTIS) study on the antioxidant capacity of a neuroprotective drug, edaravone as compared with uric acid, glutathione, and trolox. Bioorg Med Chem Lett. 2014;24:1376–9.
   PubMed Web of Science ®Google Scholar
• Spasić S, Nikolić-Kokić A, Miletić S, Oreščanin-Dušić Z, Spasić MB, Blagojević D, et al. Edaravone may prevent ferroptosis in ALS. Curr Drug Targets. 2020;21:776–80.
   PubMed Web of Science ®Google Scholar
• Blokhuis AM, Groen EJ, Koppers M, van den Berg LH, Pasterkamp RJ. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125:777–94.
   PubMed Web of Science ®Google Scholar
• Boros BD, Schoch KM, Kreple CJ, Miller TM. Antisense oligonucleotides for the study and treatment of ALS. Neurotherapeutics. 2022;19:1145–1158.
   PubMed Web of Science ®Google Scholar
• Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci. 2013;14:248–64.
   PubMed Web of Science ®Google Scholar